Benjamin Chen

Diagnostics for the Real World (Europe) Ltd. develops diagnostic tests. The firm develops cutting-edge technologies and diagnostic assays for deployment in resource poor countries primarily through patient sample testing at the point of care or near the patient. Its signal amplification technologies offer rapid and reliable tests for Chlamydia, Hepatitis and HIV. The company was founded by Helen Lee in 2002 and is headquartered in Little Chesterford, the United Kingdom.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

WEX Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceutical products for pain management. The pain management solutions are provided through its proprietary platform technology based on TTX (Tetrodotoxin). It owns and operates its research, development and manufacturing facilities in China through its subsidiaries. The company was founded on June 3, 1987 and is headquartered in Vancouver, Canada.